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       n December 2019, an outbreak of  
       unexplained pneumonia cases was reported in 
       Wuhan, China (Wuhan Municipal Health 
Commission. Report of Clustering Pneumonia of 
Unknown Etiology in Wuhan City, 2019. 
http://wjw.wuhan.gov.cn/front/web/showDetail/2019123
108989. Accessed December 31, 2019., n.d.). A few days 
later, the causative microbe in this mysterious disease was 
recognized as a novel coronavirus (nCoV) by various 
independent laboratories (Lu et al., 2020; Zhou et al., 
2020; Zhu et al., 2020). 
The causative virus has been, since, identified as severe 
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
2), and the disease it causes has been named coronavirus 
disease 2019 (COVID‐19) by the World Health 
Organization (He et al., 2020). As of 20 August 2020, 
over 22.4 million confirmed cases and over 788,000 
related deaths have been reported globally 
(https://coronavirus.jhu.edu/map.html). However, the 
true number is probably much higher than the official 
estimates based on the fact that many cases are 
asymptomatic carriers or go undiagnosed because of a 
lack of testing. 
Most of the studies indicated that patients with cancer are 
at a higher risk of COVID-19-related complications and 
death when compared with the general population (Afshar 
et al., 2020; Mehta et al., 2020; Miyashita et al., 2020). In 
this context, Kuderer et al. (2020) examined the severity 
of COVID-19 in patients with cancer (n=1035) and 
obtained the following statistics: patients admitted to the 
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intensive care unit (ICU) = 14%; patients that required 
mechanical ventilation = 12%; and death ratio = 13%. By 
contrast, these values are much lower in patients without 
cancer, namely 3.2%, 2.3%, and 3.7%, respectively 
(Meng et al., 2020). The drivers for the increased disease 
severity in patients with cancer are poorly understood. 
One study proposed that the high rate of COVID-19-
related mortality in patients with cancer are likely 
dependent on the comorbidities present before initiation 
of radiation or current anticancer therapies (Vuagnat et 
al., 2020). In this review, we discuss the known factors 
that could possibly augment the severity of COVID-19 in 
patients with cancer. We also review the current 
information about the efficiency of novel therapeutic 
options for COVID-19, specifically in patients with 
cancer.  
2. FACTORS THAT CONTRIBUTE TO THE HIGH 
MORTALITY RISK FOR COVID-19 IN PATIENTS WITH 
CANCER 
Recent studies have reported on retrospective case studies 
of COVID-19 in patients with cancer with an 
astonishingly high mortality rate (11.0%–28.6%) (Afshar 
et al., 2020; Miyashita et al., 2020; Zhang et al., 2020). 
Importantly, Dai et al. (2020) demonstrated that patients 
with hematologic cancer (leukemia, myeloma, and 
lymphoma), lung cancer, or metastatic cancer (stage IV) 
had the highest frequency of severe events, which is 
described as a condition that demands admission to the 
ICU, the use of mechanical ventilation, or can lead to 
death. Conversely, patients with nonmetastatic cancer 
experienced a similar frequency of severe conditions as 
patients without cancer (Dai et al., 2020). Although the 
investigators did not explain the rationales behind a worse 
COVID-19 outcome in patients with metastatic cancer, 
we believe that there is an increased risk in patients with 
metastatic cancer because these patients are mostly 
immune suppressed as a consequence of their treatment. 
COVID-19 leads to a cytokine release syndrome and viral 
acute respiratory distress syndrome caused by 
uncontrolled severe acute inflammation (Addeo et al., 
2020). Particularly with lung cancer, patients suffer from 
chronic pulmonary inflammation that is mainly elicited 
by the tumor microenvironment and the frequent 
underlying lung pathology (Ballaz et al., 2003; Sekine et 
al., 2012). Therefore, patients with lung cancer are prone 
to the complications of severe pathogenesis and mortality 
from COVID-19 (Dai et al., 2020; Rogado et al., 2020; L. 
Zhang et al., 2020).  
Anticancer treatment is 1 of the possible driving factors 
that is linked to COVID-19 severity in patients with 
cancer, which causes a systemic immunosuppressive state 
(Liang et al., 2020; Patel et al., 2020; Tian et al., 2020; 
van de Haar et al., 2020; C. Wu et al., 2020). Yang et al. 
(2020) have conducted an investigation to determine if 
cytotoxic chemotherapy acts as a risk factor for mortality 
in COVID-19-infected patients with cancer. Accordingly, 
it was found that cytotoxic chemotherapy enhances the 
risk for fatal outcomes from COVID-19 (Yang et al., 
2020), which is possibly caused by long-term 
myelosuppression and impaired immunity. Other studies 
obtained similar results for patients who received 
chemotherapy or underwent surgery in the 30 days before 
infection with COVID-19, according to which the 
patients were characterized to have a higher risk for 
severe events when compared with those who did not 
undergo chemotherapy or surgery (Al-Quteimat et al., 
2020; Dai et al., 2020). In order to further confirm these 
data, the United Kingdom Coronavirus Cancer 
Monitoring Project has analyzed the mortality rate in 800 
patients with cancer who were diagnosed with 
symptomatic COVID-19 (Lee et al., 2020). The obtained 
data proposed that the mortality from COVID-19 in 
patients with cancer was primarily driven by age, gender, 
and comorbidities (hypertension, cardiovascular disease, 
diabetes, and pulmonary disease) (Lee et al., 2020). 
Remarkably, they found no significant difference in the 
mortality from COVID-19 between patients with cancer 
receiving cytotoxic chemotherapy, immunotherapy, 
hormonal therapy, targeted therapy, or radiotherapy 
treatment and those not receiving active treatment (Lee et 
al., 2020). In agreement with these findings, Dai et al. 
(2020) found no difference in COVID-19 severity 
between patients with cancer, who underwent only 
radiotherapy, and patients without cancer. Thus, the effect 
of immunosuppression in patients with cancer on the 
mortality rate from COVID-19 remains controversial and 
requires further investigation. As yet, no evidence is 
available to support changing or withholding 
chemotherapy or immunotherapy in patients with cancer 
owing to a diagnosis with COVID-19. The clinical 
judgment is paramount in this decision, according to 
which the common expectation is to continue treatments, 
if lifesaving.  
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One of the major factors that most likely contribute to the 
high mortality risk associated with COVID-19 in patients 
with cancer is limited access to essential healthcare and 
an inability to receive the necessary medical services in a 
timely fashion, especially in high-risk epidemic areas, 
because of the high demand for medical staff and 
healthcare facilities (Alhalabi et al., 2020; H. Wang et al., 
2020). However, the detailed contribution to COVID-19 
mortality associated with this factor remains largely 
unknown and warrants further investigation. Taken 
together, various factors could increase the severity of 
COVID-19 in patients with cancer and the patient’s 
inherent immunity might be a decisive factor for their 
prognosis after effective supportive care.  
3. THE EFFECT OF COVID-19 SUPPORTIVE 
TREATMENTS ON THE MORTALITY RATE IN 
PATIENTS WITH CANCER 
Since no potential cure has been reported for COVID-19 
to date, the management strategies primarily focus on 
supportive treatment and protective measures to prevent 
further transmission of the virus (World Health 
Organization. Clinical management of severe acute 
respiratory infection (SARI) when COVID-19 disease is 
suspected.). Different treatment modalities are emerging 
for patients with COVID-19, although all the existing 
therapies are still being investigated. However, there is a 
big knowledge gap on how to tackle the crucial clinical 
questions about the complexities that may develop from 
the supportive treatments for COVID-19 in patients with 
cancer. Thus far, the most effective treatments for 
COVID-19 comprises corticosteroids (e.g., 
dexamethasone), tocilizumab, and remdesivir (Baden et 
al., 2020; Jafari et al., 2020; R. Wu et al., 2020). In 
addition, convalescent plasma therapy (CPT) transfusion 
is currently considered for the rescue of severely ill 
patients with COVID-19 upon hospitalization (Duan et 
al., 2020; Islam et al., 2020).  
3.1. Corticosteroids drugs 
Corticosteroids drugs including dexamethasone (Horby et 
al., 2020) are widely used as supportive treatment for 
COVID-19 (Russell et al., 2020; Villar et al., 2020). 
Various studies have suggested corticosteroids as a 
potential supportive treatment that could decrease the 
duration of mechanical ventilation and the overall 
mortality rate in patients with severe COVID-19; 
however, the evidence is inconsistent (Ye et al., 2020). 
The effect of corticosteroids on COVID-19 in patients 
with cancer is still unclear. Based on previous studies 
(Arabi et al., 2018), patients with cancer who were 
diagnosed with Middle East respiratory syndrome 
(MERS), caused by a coronavirus closely related to 
SARS-CoV-2 (Ragab et al., 2020), were more likely to 
require mechanical ventilation and vasopressors after 
administration of corticosteroid therapy including 
dexamethasone, hydrocortisone, and methylprednisolone 
(Arabi et al., 2018). Importantly, the authors concluded 
that the administration of corticosteroids did not affect the 
mortality rate (Arabi et al., 2018). It has been suggested 
that patients with cancer diagnosed with COVID-19 
might, more likely, be harmed by corticosteroid treatment 
(Russell et al., 2020). The negative effect of 
corticosteroids could be driven by their function in 
immunosuppression (Thng et al., 2020). Dexamethasone 
has been shown to attenuate immune responses in patients 
with cancer through suppression of T cell proliferation 
and differentiation (Giles et al., 2018). Thus, further 
investigations are required to shed more light on the role 
of dexamethasone in the treatment of COVID-19 in 
patients with cancer. 
3.2. Tocilizumab 
Tocilizumab is a humanized monoclonal antibody that 
acts against both soluble and membrane-bound forms of 
the interleukin-6 (IL-6) receptor (Venkiteshwaran, 2009). 
Tocilizumab is recommended for treating severe 
rheumatoid arthritis (Smolen et al., 2008). Tocilizumab 
has also been approved as a therapy for chimeric antigen 
receptor T-cell-therapy-induced cytokine release 
syndrome (Kewan et al., 2020). Cytokine release 
syndrome is caused by an uncontrolled immune activation 
that is characterized by the occurrence of a “cytokine 
storm” (Lee et al., 2014), which is similar to the type seen 
in the most severe cases of COVID-19 (Levi, 2020). 
Alattar et al. (2020) reported that administration of 
tocilizumab in patients with severe COVID-19 is 
correlated with a dramatic decline in inflammatory 
markers, radiological improvement, and reduced 
ventilatory support requirements (Alattar et al., 2020). 
Other studies from China (Jafari et al., 2020; Wu et al., 
2020) and the United States (Kewan et al., 2020) have 
also supported these results and confirmed that 
tocilizumab could induce recovery in patients with severe 
UKH Journal of Science and Engineering | Volume 4 • Number 2 • 2020 121 
Qusairy and Rada: COVID-19 Severity in Patients with Cancer 
  
cases of COVID-19 (Jafari et al., 2020; R. Wu et al., 
2020). Despite being recommended as a promising 
treatment in COVID-19 patients with cancer (Ascierto et 
al., 2020; Levi, 2020), very little is known about 
tocilizumab’s efficacy and interaction with anticancer 
therapeutic agents. Therefore, more studies to assess the 
efficacy of tocilizumab in the population with cancer are 
needed. Indeed, a prospective, randomized multicenter 
study is currently recruiting patients with advanced or 
metastatic cancer who have been diagnosed with COVID-
19 across Europe (NCT04333914), and tocilizumab is 
among the agents that are proposed in this investigation.  
3.3. Remdesivir 
Early in 2020, the Wuhan Virus Research Institute 
proposed remdesivir as the fastest-acting and most 
powerful antiviral agent against COVID-19 in vitro (Cao 
et al., 2020). Remdesivir, a nucleoside analog antiviral 
agent that perturbs viral replication by blocking RNA 
polymerase, has shown the ability to inhibit replication in 
various types of coronaviruses including those that cause 
MERS and severe acute respiratory syndrome (Eastman 
et al., 2020; Yeoh et al., 2020). Early clinical trials of 
remdesivir treatment for COVID-19 were conducted in 
Hubei, China, between February 6, 2020, and March 12, 
2020, and enrolled 237 patients (158 to remdesivir and 79 
to placebo)(Y. Wang et al., 2020). Importantly, the 
clinical benefits of remdesivir in patients with COVID-19 
were statistically insignificant (Y. Wang et al., 2020). On 
April 3, 2020, the European Medical Agency approved 
remdesivir treatment for patients with COVID-19 
requiring mechanical ventilation (Singh et al., 2020). The 
clinical trial results showed that there may be a benefit to 
using remdesivir compared with the placebo in severe 
COVID-19 cases (Davies et al., 2020; Grein et al., 2020). 
Additionally, remdesivir has also been suggested as a 
potential inhibitor of viral infection in a human liver 
cancer (Huh-7) cell line (Wang et al., 2020). However, no 
data are available to show the effect of remdesivir 
treatment in patients with cancer diagnosed with COVID-
19.  
3.4. Convalescent Plasma Therapy Transfusion 
CPT was used for the first time by von Behring and 
Kitasato as a rational approach to treat diphtheria in 1890 
(Behring et al., 1890). Initially, convalescent plasma was 
obtained from individuals who recovered from the viral 
infection and were able to donate their antiviral 
immunoglobulin-containing blood; once transfused into 
the patient suffering from active infections, the antibodies 
from the convalescent plasma are thought to neutralize 
the virus and limit its replication and, consequently, 
reduce the symptoms and mortality (Behring et al., 1890; 
Luke et al., 2010; Rojas et al., 2020). Historical evidence 
demonstrated CPT to be a highly effective treatment for 
influenza pneumonia and what is now known as acute 
respiratory distress syndrome during the Spanish 
influenza pandemic (Bass et al., 1919; Redden, 1919; 
Sanborn, 1920).  
The COVID-19 pandemic has placed emphasis on CPT to 
treat infectious diseases. Recent investigations from 
China demonstrated that human covalescent plasma is a 
potential therapeutic option that can decrease the severity 
and/or shorten the length of illness caused by SARS-
CoV-2 (Duan et al., 2020; Shen et al., 2020; M. Ye et al., 
2020; Zeng et al., 2020; B. Zhang et al., 2020). The 
majority of the findings suggested that CPT therapy in 
patients with COVID‐19 appears to be safe and clinically 
effective in reducing mortality (Islam et al., 2020; 
Rajendran et al., 2020; Rojas et al., 2020; R. Wu et al., 
2020). It is worth mentioning that the majority of these 
studies have used small sample sizes that ranged between 
4 and 10 patients (Duan et al., 2020; Shen et al., 2020; M. 
Ye et al., 2020; Zeng et al., 2020; B. Zhang et al., 2020). 
However, a recent multicenter study that was conducted 
in the USA by Mayo Clinic researchers examined the 
effect of CPT on 20,000 patients hospitalized with 
COVID-19 across the USA between April 3, 2020, and 
June 2, 2020 (Joyner et al., 2020). The data support the 
notion that CPT is safe in hospitalized patients with 
COVID-19 and earlier administration of plasma within 
the clinical course of COVID-19 is more likely to reduce 
mortality. Indeed, the Food and Drug Administration has 
issued an emergency-use authorization for emergency use 
of COVID-19 convalescent plasma for the treatment of 





CPT in patients with cancer diagnosed with COVID-19 
has also shown high levels of efficacy. Based on the study 
by Hatzl et al. (2020), convalescent plasma has been used 
for 2 patients with COVID-19 with hematological cancer 
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(patient #1: diffuse large B-cell lymphoma; patient #2: 
follicular lymphoma) who have been on mechanical 
ventilation for 6 and 11 days, respectively. Impressively, 
both patients were off the ventilator 5 and 4 days after CP 
therapy, respectively (Hatzl et al., 2020). Moreover, the 
levels of inflammatory markers including IL-6 and serum 
ferritin also decreased dramatically (Hatzl et al., 2020). 
Although, the sample size does not allow any definitive 
conclusions to be drawn, these data provide continued 
optimism regarding the safety of COVID-19 convalescent 
plasma. However, we believe that using CPT in patients 
with cancer may provide some challenges, such as 
transfusion-related acute lung injury, circulatory 
overload, and hemolysis. Therefore, further investigation 
is warranted to get a more comprehensive picture. 
4. CONCLUSIONS 
The current review is based on the latest information 
available for this field at this time. The available data are 
insufficient to draw statistical and generalizable 
conclusions about the factors that might be correlated 
with better or worse outcomes for patients with cancer. 
The mortality rate of COVID-19 in patients with cancer 
should be interpreted with caution because of the limited 
information in some primary studies, for example, it is 
unclear if all the deaths were caused by COVID-19, 
cancer, or other comorbidities. Moreover, the majority of 
these studies analyzed small cohorts. In addition, some 
studies did not consider the cancer types, stages, and 
treatments. Furthermore, their samples comprised only 
hospitalized patients with cancer, whereas patients with 
cancer who died from COVID-19 outside the hospital 
setting were missed.  
Based on the findings that we reviewed in this 
minireview, we recommend diligent preventive-care 
measures, as well as full supportive care for 
immunosuppressed patients to decrease the risk of 
infection. We believe that there is an urgent need for well-
designed investigations to determine the management and 
treatment of COVID-19 in the oncology setting, as well 
as identify the clinical effects of continuing or 
withholding cancer therapy in patients with cancer 
diagnosed with COVID-19. Importantly, future studies 
should use large-scale datasets and pay attention to the 
detailed characteristics of infected patients with cancer, 
such as the cancer types and stages, chemotherapy or 
radiation-related variables, inflammatory profile, and care 
protocols that are followed during COVID-19 stages.  
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